Find Funding Opportunities

Purpose. Under this Funding Opportunity Announcement (FOA), the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Aging (NIA), National Institute of Mental Health (NIMH), and the National Institute of Nursing Research (NINR) invite research grant applications that address the underlying neurobiological mechanisms associated with cognitive impairment and mood disturbance in Parkinson's disease (PD), that address the development of clinical interventions and therapeutics for cognitive impairment and affective symptoms in PD, or that promote improved clinical diagnosis or treatment of cognitive and affective impairment in PD. A goal of this FOA is to begin a process where basic and clinical scientists from various disciplines can overcome barriers to cross-disciplinary and biobehavioral research and examine all aspects of cognition and affective regulation in the context of the diagnosis and treatment of Parkinson's disease.

Purpose. Under this Funding Opportunity Announcement (FOA), the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Aging (NIA), and the National Institute of Mental Health (NIMH) invite research grant applications to develop new, or improve existing, animal models which address the underlying neurobiological mechanisms associated with cognitive impairment and mood disturbance in Parkinson's disease (PD), that assist in the development of clinical interventions and therapeutics for cognitive impairment and affective symptoms in PD, or that promote improved treatment of cognitive and affective impairment in PD. A goal of this FOA is to begin a process where basic and clinical scientists from various disciplines can overcome barriers to cross-disciplinary and biobehavioral research and examine all aspects of cognition and affective regulation in the context of the diagnosis and treatment of Parkinson's disease. Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism and runs in parallel with a FOA of identical scientific scope, PA-09-033, that encourages applications under the R01 mechanism. Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism, numbers, quality, duration, and costs of the applications received.

Purpose This FOA is issued by the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health. This FOA is a follow up of a previous Roadmap RFA (RM-04-021 Innovation in Molecular Imaging Probes). The purpose of this initiative is to encourage the development of novel molecular imaging approaches that can detect and image specific molecular activities in vivo, and have the potential for clinical applications.Novel molecular imaging approaches developed through this initiative can focus on one (or both) of the following long-term translational goals: (1) imaging the characteristic markers, and function, of normal cells in control human subjects and patients, and (2) imaging the characteristic markers, and biochemical or physiological abnormalities, of disease cells in patients.Potential abnormalities that could provide early markers for disease include (but are not restricted to): inflammation, fibrosis, immune cell activation, altered signal transduction pathways, altered gene expression pathways, and altered post-translational modification of proteins.This initiative solicits applications that explore innovative high-impact approaches, rather than incremental technology development that is already supported by current NIH programs. Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism with a 12 page limit for the research plan. Funds Available and Anticipated Number of Awards.Awards issued under this FOA are contingent upon the availability of funds.The total amount awarded and the number of grants will depend upon the quality, duration and costs of the applications received.

Purpose. This FOA issued by the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Neurological Disorders and Stroke (NINDS) solicits Research Project Grant (R01) applications from institutions/organizations that propose to conduct basic and translational research into the neurobiology of pain in sickle cell disease. Applications that promote multidisciplinary collaboration are strongly encouraged. Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) grant mechanism. Funds Available and Anticipated Number of Awards. NHLBI intends to commit up to $6.0 million (total costs) over four years and NINDS intends to commit up to $1.4 million (total costs) over four years.The NHLBI and NINDS anticipate that they will award up to $1.85 million in FY 2009 to fund four applications in response to this FOA.Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

-Purpose. The purpose of this Funding Opportunity Announcement (FOA) issued by the National Institute on Drug Abuse (NIDA) and the National Institute of Neurological Disorders and Stroke (NINDS) is to issue a Request for Applications (RFA) to investigate CNS changes that occur with chronic pain, and how these changes parallel those that occur with drug addiction. Of interest will be how chronic pain changes the CNS, how analgesics of various classes impact pain-induced CNS changes, and how analgesics in the absence of pain (some of which have abuse potential) produce CNS changes. The temporal course of these changes will also be of interest.A focus of this research will be comparing and contrasting these CNS changes in an effort to identify shared and unique mechanisms involved in pain, analgesia and drug abuse, as well as environmental and genetic factors that influence these changes. -Mechanism of Support. This FOA will utilize the R01 grant mechanism and runs in parallel with two FOAs of identical scientific scope, RFA-DA-09-018 (http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-09-018) and RFA-DA-09-019 (http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-09-019), that solicit applications under the R21 and R03 mechanisms, respectively.

-Purpose. The purpose of this Funding Opportunity Announcement (FOA) issued by the National Institute on Drug Abuse (NIDA) and the National Institute of Neurological Disorders and Stroke (NINDS) is to issue a Request for Applications (RFA) to investigate CNS changes that occur with chronic pain and how these changes parallel those that occur with drug addiction. Of interest will be how chronic pain changes the CNS, how analgesics of various classes impact pain-induced CNS changes, and how analgesics in the absence of pain (some of which have abuse potential) produce CNS changes. The temporal course of these changes will also be of interest.A focus of this research will be comparing and contrasting these CNS changes in an effort to identify shared and unique mechanisms involved in pain, analgesia and drug abuse, as well as environmental and genetic factors that influence these changes. -Mechanism of Support. This FOA will utilize the R21 grant mechanism and runs in parallel with two FOAs of identical scientific scope, RFA-DA-09-017 (http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-09-017) and RFA-DA-09-019 (http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-09-019), that solicit applications under the R01 and R03 mechanisms, respectively. -Funds Available and Anticipated Number of Awards. The NIDA has set aside $2,000,000 to fund an anticipated 6-10 grant applications and the NINDS has set aside $375,000 to fund an anticipated two grants for this FOA and its companion R01 and R03.

-Purpose. The purpose of this Funding Opportunity Announcement (FOA) issued by the National Institute on Drug Abuse (NIDA) and the National Institute of Neurological Disorders and Stroke (NINDS) is to issue a Request for Applications (RFA) to investigate CNS changes that occur with chronic pain, and how these changes parallel those that occur with drug addiction. Of interest will be how chronic pain changes the CNS, how analgesics of various classes impact pain-induced CNS changes, and how analgesics in the absence of pain (some of which have abuse potential) produce CNS changes. The temporal course of these changes will also be of interest.A focus of this research will be comparing and contrasting these CNS changes in an effort to identify shared and unique mechanisms involved in pain, analgesia and drug abuse, as well as environmental and genetic factors that influence these changes. -Mechanism of Support. This FOA will utilize the R03 grant mechanism and runs in parallel with two FOAs of identical scientific scope, RFA-DA-09-017 (http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-09-017) and RFA-DA-09-018 (http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-09-018), that solicit applications under the R01 and R21 mechanisms, respectively. -Funds Available and Anticipated Number of Awards. The NIDA has set aside $2,000,000 to fund an anticipated 6-10 grant applications and the NINDS has set aside $375,000 to fund an anticipated two grants for this FOA and its companion R01 and R21.

-Purpose. This funding opportunity announcement (FOA), administered by the National Cancer Institute, is a part of the Genes, Environment, and Health Initiative (GEI, http://www.gei.nih.gov/) sponsored by the National Institutes of Health (NIH). The purpose of this FOA is to provide support for replication and fine-mapping studies of genetic regions that are putatively associated with common complex traits, primarily those identified by genome-wide association studies (GWAS). The proposed projects should aim to enhance the identification of causal variants influencing complex diseases. Any phenotype may be appropriate for these projects (i.e., studies need not be oriented on cancer or cancer-related phenotypes). This FOA will not support recruitment of human subjects, collection of human specimens, collection of medical or phenotype data, studies using animal models, or discovery genome-wide association efforts. -Mechanism of Support. This FOA will utilize the NIH research project (R01) grant mechanism. -Funds Available and Anticipated Number of Awards. The NCI has set aside $2 million in Fiscal Year 2009 for 4-6 awards under this FOA.

-Purpose. This FOA invites R01 applications for mechanistic studies in clinical trials of: (1) immunomodulatory interventions for immune system mediated diseases, including, but not limited to: asthma and allergic diseases; graft rejection in solid organ, cell, and tissue transplantation; graft versus host disease in hematopoietic stem cell transplantation; and chronic inflammatory, autoimmune, and immunodeficiency diseases; and (2) preventative and therapeutic, vaccines for non-HIV/AIDS infectious diseases, including NIAID Category A, B, and C agents of bioterrorism and emerging/re-emerging infectious diseases. This FOA is a renewal with modifications of RFA AI-05-028 (http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-05-028.html). In order to review and confer awards to grant applications received in response to this FOA in a timely fashion, without delay of the parent clinical trial, applications submitted in response to the FOA will be subject to an accelerated review/award process. Highly meritorious applications selected for funding under this FOA may receive their awards as early as thirteen weeks after the application receipt date. Holidays and other circumstances may alter this schedule slightly. -Mechanism of Support. This FOA will utilize the NIH Research Project grant (R01) mechanism.

-Purpose. This Funding Opportunity Announcement (FOA) issued by the Office of Research on Women's Health (ORWH) and co-sponsoring Institutes and Centers (ICs) of the National Institutes of Health (NIH) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology, and treatment of chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME/CFS) in diverse groups and across the lifespan. Innovative applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among patient populations, and the common mechanisms influencing the multiple body systems that are affected in CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of the disease process and provide evidence based solutions to improve the diagnosis, treatment, and quality of life of all persons with CFS. -Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism and runs in parallel with a FOA of identical scientific scope, PA-08-247, that encourages applications under the NIH Exploratory/Developmental (R21) grant mechanism. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. -Budget and Project Period. Budget and Project Period. The total project period for an application submitted in response to this funding opportunity may not exceed 5 years.